AbbVie Inc vs SMX Security Matters plc — how do they compare? AbbVie Inc trades at $248.33 (market cap $441.94B), while SMX Security Matters plc trades at $16.48 (market cap $17.04M). The key difference: AbbVie Inc is far larger — about 25935.4× SMX Security Matters plc's market cap, and AbbVie Inc pays a 2.77% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals.
| ABBV | SMX | |
|---|---|---|
Market Cap | $441.94B | $17.04M |
Sector | Health | Technology |
52-Week High | $263.58 | $103.71K |
52-Week Low | $197.38 | $12.87 |
Enterprise Value | $506.19B | -$14.29M |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
SMX trades at $16.45, up 4.11% today, amid a reverse stock split effective June 1, 2026. The stock shows bearish technical signals with support at $16 and resistance at $17. Financially, the company reported a net loss of $169.18 million for 2025, with negative ROE and ROA, though it strengthened its balance sheet with $77 million in financing in 2026. Recent news highlights SMX's focus on recycled plastic verification and commercialization strategies.
The outlook remains speculative; SMX's technology addresses growing demand for material traceability, but persistent losses and high cash burn pose significant risks. Investor sentiment is cautious due to weak profitability, though institutional financing provides near-term liquidity. The stock's viability hinges on successful commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →